ThursdayFeb 22, 2024 11:00 am

Psychedelics Take Different Commercialization Approach from Marijuana

The growing psychedelic industry is charting its own path to commercialization instead of following cannabis’ footprints. The psychedelics industry is basing its approach on facts and research, unlike cannabis, which centered on legalization. Experts in the psychedelic field have been conducting research on the substances for decades now, which has led to the discovery of various benefits that psychedelics hold. Researchers started studying psychedelics in the 1950s, until two decades later when the Controlled Substances Act came into effect. This act made it illegal to hold, much less carry out research on these compounds, which were classified into different schedules.…

Continue Reading

TuesdayFeb 20, 2024 9:45 am

Researchers Look into Possibility of Treating Borderline Personality Disorder Using Psychedelics

Researchers are considering the possibility of using psychedelic drugs such as MDMA to treat Borderline Personality Disorder (BPD). BPD is a debilitating mental disorder that hinders an individual’s ability to manage emotions and leads to high impulsivity; it also generally negatively affects relationships. People with BPD often have long-term feelings of emptiness and find it difficult to form a stable sense of identity. This can result in impulsive behaviors and self-destructive tendencies, including suicidal thoughts or self-harm. Intense fear of abandonment also leads to stormy and volatile relationships characterized by devaluation and idealization of partners. Current treatment protocols for borderline…

Continue Reading

TuesdayFeb 13, 2024 10:45 am

Seizures of Magic Mushrooms by Authorities Rose as Demand Grew

In the last couple of years, we have seen interest in psychedelics increase as more studies uncover their hidden benefits. Interest in psilocybin, the psychoactive compound found in hallucinogenic mushrooms, has increased significantly following evidence of its benefits for a range of mental-health conditions, including post-traumatic stress disorder and depression. However, drug busts of magic mushrooms have also increased, with data from new research showing that the amount of psilocybin seized by authorities has more than tripled in the period between 2017 and 2022. The author of this new research, Joseph Palamar, stated that the study’s findings indicated that the…

Continue Reading

ThursdayFeb 08, 2024 10:45 am

Study Finds Psychedelic Users More Prone to Unusual Visual Experiences

Research into psychedelics has increased significantly in the recent past, with growing evidence to support their therapeutic benefits for a range of disorders, among them alcoholism and depression. Now, a new study has found that people who use psychedelics such as psilocybin and LSD may experience increased unusual visual occurrences. The study looked into the possible side effects of psychedelics when used in a recreational setting. The focus outside of clinical settings comes from concern that using these drugs in uncontrolled environments may not be safe. For their research, the scientists looked into the intensity and prevalence of visual experiences…

Continue Reading

TuesdayFeb 06, 2024 10:45 am

Exploring Gender Challenges within Nascent Psychedelics Industry

Most psychedelic research is still in its infancy and is concerned with understanding the mechanisms that allow psychedelics such as LSD and psilocybin mushrooms to deliver a myriad of mental health benefits. The existing body of scientific literature on the subject has found that several classic psychedelics have the potential to offer long-term relief against hard-to-treat mental disorders, including treatment-resistant depression and post-traumatic stress disorder. However, several questions about psychedelics remain. Of these questions, a commonly asked one is whether different genders respond to psychedelics differently. Do women respond differently to psychedelic-based treatments than men? Furthermore, how can physicians account…

Continue Reading

MondayFeb 05, 2024 10:30 am

Canadian Companies Set to Reap Big from Psychedelics Exports to Australia

Several Canadian biotechnology companies are poised to make a killing in the Australian market after the county’s Therapeutic Goods Administration (TGA) allowed psychiatrists to prescribe MDMA and psilocybin in 2023. The TGA regulates therapeutic goods such as medical devices and prescription drugs in Australia. It approved the prescription of psilocybin, the main psychoactive agent in magic mushrooms, and MDMA by changing their classification in Australia’s Poisons Scheme. The TGA’s changes to the Poisons Scheme mean that the two psychedelics are considered Schedule 8 Controlled Drugs for specific uses. However, psilocybin and MDMA will remain in Schedule 9 (Prohibited Substances), which…

Continue Reading

FridayFeb 02, 2024 1:21 pm

Hawaii Task Force Files Bill Creating Program for Medicinal Psilocybin Use

Hawaii recently introduced a new measure that would establish legal protections for psilocybin’s therapeutic use. Under SB 3019, eligible patients would be allowed to possess the psychedelic and receive it under the care of a trained facilitator. The legislation, which was sponsored by Senator Chris Lee, was introduced by a task force formed in 2023 to look into breakthrough therapies. While the measure won’t legalize the psychedelic, it would defend eligible patients and their caregivers from state laws against psilocybin. Under SB 3019, mental health professionals would be allowed to recommend therapeutic psilocybin for individuals who met the stipulated eligibility…

Continue Reading

ThursdayFeb 01, 2024 2:30 pm

Why Psychedelics Could Encounter Regulatory Roadblocks at State, Federal Levels

A recent influx in psychedelic-related research has revealed that some classic psychedelic drugs have the potential to offer long-term relief against several mental disorders. The expanding scientific literature states that psychedelics such as LSD, psilocybin (magic mushrooms) and ayahuasca may be able to treat debilitating mental disorders, including treatment-resistant depression, eating disorders and post-traumatic stress disorder (PTSD). As a result, there have been growing calls to legalize therapeutic psychedelic use to provide mental-health patients with access to safer and more effective alternative treatments. However, regulatory roadblocks at the state and federal levels could frustrate efforts to legalize psychedelics for therapeutic…

Continue Reading

WednesdayJan 31, 2024 12:38 pm

Mouse Study Shows Microdoses of Psilocybin Can Combat Anhedonia

Researchers from the University of Southern Denmark have discovered that microdoses of psilocybin, the main psychoactive agent in mushrooms, may be able to alleviate anhedonia. The study used a mouse study to discover that regular small doses of the psychedelic may offer therapeutic benefits against stress-induced anhedonia, a condition that strips individuals of their ability to feel pleasure, and compulsive behavior. Furthermore, psilocybin exhibited therapeutic effectiveness in mice with anhedonia and compulsive behaviors without inducing side effects such as schizophrenia-like symptoms and anxiety. The University of Southern Denmark University team published its findings in the “Molecular Psychiatry” journal. Most of…

Continue Reading

MondayJan 29, 2024 1:21 pm

EU Finances First Psychedelics Research on Incurable Illnesses

The European Union (EU) is funding research into psychedelic-based therapies for patients with incurable diseases. Researchers will use EU funding to determine if psychedelic drugs such as psilocybin can help alleviate psychologic distress in palliative-care patients. While palliative and end-of-life care are designed to relieve physical symptoms and make patients as comfortable as possible, there aren’t a lot of protocols to alleviate the psychological distress that often accompanies incurable illnesses. Psychedelics have exhibited significant potential as mental-health treatments in several initial studies and have shown that they can treat significant mental distress in conditions such as depression and post-traumatic stress…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050